Medicine
Avaclyr 3% eye ointment
Avaclyr 3% eye ointment is a prescription medicine containing Acyclovir for ophthalmic use, marketed by Fera Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15°C to 25°C (59°F to 77°F).
Key facts
- Active ingredient (INN)
- Acyclovir
- Brand
- Avaclyr
- Strength
- 3%
- Dosage form
- Eye ointment
- Route
- Ophthalmic
- Packs
- 1 tube
- Marketing authorisation holder
- Fera Pharmaceuticals
- Manufacturer
- Fera Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 15°C to 25°C (59°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D06BB03 Acyclovir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 January 2026
- Identifiers
- RxCUI 199413, 2734142DailyMed set ID 3ce26231-bc40-48b0-85e5-2e7622f334d7NDC 48102-028Application NDA202408
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 tube in 1 carton / 3.5 g in 1 tube | 48102-028-35 | Fera Pharmaceuticals | 31 January 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 March 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Acyclovir
Clinical summary
Acyclovir is a herpes simplex virus nucleoside analog DNA polymerase inhibitor indicated in the management of initial genital herpes and in limited non-lifethreatening mucocutaneous HSV infections in immunocompromised patients. MedsAcross supplies Acyclovir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AcyclovirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zovirax prescribing information (Bausch Health) · U.S. National Library of Medicine, DailyMed
Need Avaclyr 3% eye ointment for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.